• Cell Therapy Shows Promise in Third-Line MSS Colorectal Cancer

    A phase 2B trial evaluated AlloStim®, an allogeneic activated memory Th1 cell therapy designed to convert "cold" tumors to "hot," in third-line MSS/pMMR metastatic colorectal cancer patients. (Translational Oncology)